Posted by Michael Wonder on 19 Feb 2020
European Commission approves Vyndaqel, the first treatment in the EU for transthyretin amyloid cardiomyopathy (ATTR-CM)
19 February 2020 - Vyndaqel is the only EC-approved medicine proven to reduce mortality and frequency of cardiovascular-related hospitalisations in adults with wild-type or hereditary ATTR-CM.
Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Vyndaqel is the first and only treatment approved in the European Union for patients with ATTR-CM. Prior to this approval, treatment options for patients with ATTR-CM were restricted to symptom management, and, in rare cases, heart (or heart and liver) transplant.
